Beam Therapeutics, a leading biotechnology company focused on developing precision genetic medicines, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its breakthrough therapy BEAM-101. This game-changing therapy is being developed to treat Sickle Cell Disease (SCD), a severe hereditary blood disorder that affects approximately 100,000 people in the […]

Beam Therapeutics Inc. (NASDAQ: BEAM) is poised to reveal transformative new data from the BEACON Trial on sickle cell disease at the EHA2025 conference. This presentation represents a significant milestone in the biotechnology and therapeutics landscape, highlighting the latest developments in treating this genetic disorder. Sickle cell disease, a debilitating condition affecting millions globally, leads […]